Skip to main content
Figure 3 | Trials

Figure 3

From: Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial

Figure 3

Course of inclusion. This figure shows at which frequency the patients entered the trial. In the first 5 months of inclusion was very rapid, but then went flat for a few months. At month 11 the protocol was changed to such an extent that ADPKD patients were also allowed to participate in the trial. This reignited inclusion and the intended sample size was reached within 3 months.

Back to article page

Trials

ISSN: 1745-6215